

# Role of microRNAs in remodeling the tumor microenvironment (Review)

ZHAOJI PAN<sup>1\*</sup>, YIQING TIAN<sup>2\*</sup>, GUOPING NIU<sup>1</sup> and CHENGSONG CAO<sup>1</sup>

<sup>1</sup>Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221000; <sup>2</sup>Xinyi People's Hospital, Xuzhou, Jiangsu 221400, P.R. China

Received July 18, 2019; Accepted December 17, 2019

DOI: 10.3892/ijo.2019.4952

**Abstract.** MicroRNAs (miRNAs) are short non-coding RNAs that are known to regulate gene expression at the post-transcriptional level. miRNA expression is often deregulated in several human cancers, affecting the communication between tumor stroma and tumor cells, among other functions. Understanding the role of miRNAs in the tumor microenvironment is crucial for fully elucidating the molecular mechanisms underlying tumor progression and exploring novel diagnostic biomarkers and therapeutic targets. The present review focused on the role of miRNAs in remodeling the tumor microenvironment, with an emphasis on their impact on tumor growth, metastasis and resistance to treatment, as well as their potential clinical applications.

## Contents

1. Introduction
2. Role of miRNAs in regulating TME cells
3. Role of TME-derived miRNAs in regulating tumor progression
4. Clinical applications of tumor-associated miRNAs
5. Conclusion

## 1. Introduction

Over the past decade, several studies have demonstrated that cancer initiation and progression are determined not only by cancer cells, but also by the tumor microenvironment (TME) (1-4), which includes fibroblasts, immune cells and endothelial cells, among others (5). Mounting evidence suggests that microRNAs (miRNAs) play a key role in shaping the biology and function

of tumor stromal cells (5-8). The deregulation of miRNAs has been associated with almost every aspect of cancer initiation and progression (9-11). In 2006, Volinia *et al* first identified a miRNA signature in human cancers and demonstrated that the predicted targets of these deregulated miRNAs were classic oncogenes or tumor suppressors (12). One of the oncogenic miRNAs identified was miR-21, which was found to be highly expressed in breast and colon cancer, and its overexpression was correlated with poor patient survival. Furthermore, miR-21 was demonstrated to target programmed cell death 4, an apoptosis-inducing protein, thus promoting tumor growth (13,14). Additionally, miR-34a was identified as a downstream target of the p53 tumor suppressor gene (15). With the recent advances in miRNA detection techniques, cancer cell-derived miRNAs have emerged as promising diagnostic biomarkers and therapeutic targets, as has been described in detail elsewhere (16-18).

Recent studies have highlighted the significance of miRNAs in the TME (19-24). Aprelikova *et al* identified 11 miRNAs that were differentially expressed between cancer-associated fibroblasts (CAFs) isolated from human endometrial cancer and normal endometrial fibroblasts (25). Mesenchymal stem cells (MSCs) were previously isolated from gastric cancer (GC) tissues (GC-MSCs) and paired adjacent non-cancerous gastric tissues (GCN-MSCs), and 114 upregulated and 85 downregulated miRNAs were identified in GC-MSCs (26). Liu *et al* compared the miRNA expression profiles of myeloid-derived suppressor cells (MDSCs) from breast cancer-bearing mice and their counterparts from tumor-free mice, and found that 3 miRNAs (miR-494, miR-882 and miR-361) were upregulated, whereas 5 miRNAs (miR-466, let-7e, miR-133b, miR-713 and miR-322) were downregulated in the MDSCs from the tumor-bearing mice. Furthermore, 5 miRNAs were found to be upregulated and 7 miRNAs downregulated in cancer-associated endothelial cells compared with normal endothelial cells (27). The aim of the present review was to summarize the latest advances in understanding the roles of miRNAs in TME remodeling, which ultimately affects tumor progression and may be of value in the clinical setting.

## 2. Role of miRNAs in regulating TME cells

*miRNAs in regulating CAFs.* Fibroblasts are one of the major components of the TME. At the primary tumor site, fibroblasts acquire distinct phenotypic characteristics and become CAFs

*Correspondence to:* Dr Yiqing Tian, Xinyi People's Hospital, 16 Renmin Road, Xinyi, Xuzhou, Jiangsu 221400, P.R. China  
E-mail: 824303893@qq.com

\*Contributed equally

**Key words:** microRNAs, tumor microenvironment, tumor progression, biomarker, targeted therapy, non-coding RNA

through a miRNA-mediated regulation of multiple signaling pathways. CAFs differ from normal fibroblasts (NFs) in their high expression of  $\alpha$ -smooth muscle actin and their pro-tumorigenic properties (28). CAFs secrete a wide range of pro-inflammatory molecules, including interleukins, chemokines and extracellular matrix (ECM) components, ultimately promoting tumor growth by modulating tumor-associated inflammation or directing cell-to-cell communication (29). Bronisz *et al* reported that miR-320 expression was significantly reduced when phosphatase and tensin homolog (*PTEN*) on chromosome 10 was ablated, which induced the transition of NFs to CAFs in breast cancer (30). Loss of the *PTEN* gene in stromal fibroblasts results in the activation of an oncogenic secretome. The downregulation of miR-320 and upregulation of one of its direct targets, ETS proto-oncogene 2, transcription factor, are critical events in *PTEN*-deficient stromal fibroblasts that induce the oncogenic secretome, which in turn promotes tumor angiogenesis and tumor cell invasion (30).

In breast cancer, the pro-metastatic miRNA miR-9 was shown to induce a switch in human breast fibroblasts from a normal towards a CAF phenotype, thereby contributing to tumor progression (31). In addition, the downregulation of miR-200s was reported to play an important role in reprogramming NFs into CAFs. miR-200s target friend leukemia virus integration 1 (Fli-1) and transcription factor 12 (TCF12) in the breast cancer microenvironment (32,33). Moreover, decreased miR-205 was shown to convert breast NFs into CAFs by promoting Yes-associated protein 1 (YAP1) expression, which has been proven to be involved in angiogenesis (34).

In ovarian cancer, low expression of miR-214 and high expression of miR-155 are involved in reprogramming quiescent fibroblasts to CAFs. miR-214 directly targets C-C motif ligand 5 (CCL5), which is essential for CAF function. The overexpression of miR-155 in NFs induces fibroblasts to develop CAF-like phenotypes. The disruption of these miRNAs is sufficient to reverse the functions of CAFs, thereby reducing ovarian cancer growth and metastasis (32). Furthermore, miR-155 was shown to convert NFs into CAFs in pancreatic cancer by targeting p53-inducible nuclear protein 1 (35).

In melanoma, melanocytes are specialized in producing pigment vesicles, referred to as melanosomes. Melanosomes have been shown to carry miRNAs, including miR-211, into primary fibroblasts, triggering changes such as increased proliferation, migration and pro-inflammatory gene expression, all of which are known characteristics of CAFs (36).

In lung cancer, downregulation of miR-1 and miR-206, and upregulation of miR-31, may promote the NF-CAF switch by stimulating CCL2/vascular endothelial growth factor A (VEGFA) expression (37). Taken together, these findings underline the importance of miRNAs in driving the conversion of NFs into CAFs in several tumor entities.

**Role of miRNAs in regulating tumor-associated MSCs.** MSCs are progenitor cells that are known to participate in tumor stroma formation and tumor progression. Bone marrow-derived MSCs (BM-MSCs) can migrate to tumor sites, where they exert tumor-promoting and pro-metastatic effects. We previously demonstrated that miR-155-5p downregulation induced BM-MSCs to acquire the phenotype of GC-MSCs through the activation of nuclear factor- $\kappa$ B p65 (NF- $\kappa$ B p65). In that study,

NF- $\kappa$ B p65 and the inhibitor of NF- $\kappa$ B kinase subunit  $\epsilon$  were identified as the targets of miR-155-5p (38). miR-214, miR-221 and miR-222 were upregulated in GC-MSCs compared with GCN-MSCs. GC-MSCs significantly promoted the proliferation and migration of GC cells. Targeted inhibition of miR-221 in GC-MSCs was found to inhibit its tumor-promoting effects (26).

Let-7 is downregulated in prostate cancer-associated MSCs, which exhibit a stronger propensity for migration and invasion compared with normal MSCs. Interleukin (IL)-6 was identified as a direct target gene of let-7. The overexpression of let-7 reduces IL-6 expression and represses the metastasis-promoting activity of cancer-associated MSCs (39). miR-146a overexpression leads to increased secretion of chemotactic proteins, including CXCL1, interferon gamma-induced protein 10, CCL5 and IL-6, which are crucial for the growth and migration of multiple myeloma cells. The Notch pathway was also shown to be involved in the miR-146a-induced cytokine and chemokine secretion in MSCs (40). In myeloid neoplasms, miR-7977 in MSCs was found to induce aberrant reduction of hematopoietic growth factors, including Jagged-1, stem cell factor and angiopoietin-1, thereby reducing the hematopoietic-supporting capacity of bone marrow CD34<sup>+</sup> cells (41). This evidence indicates that the aberrant expression of miRNAs can promote the evolution of MSCs in the TME, facilitating tumor progression.

**Role of miRNAs in regulating tumor-associated macrophages.** Tumor progression is intrinsically linked to immune evasion. The activation of certain immune cells drives potent antitumor responses, whereas the suppression of these cells promotes tumor progression and metastasis. Cancer cells can regulate miRNA expression in infiltrating immune cells, thereby suppressing the local antitumor immune response and ultimately leading to tumor progression (42-47). Tumor-associated macrophages (TAMs) have both pro- and anti-tumorigenic properties, depending on whether they belong to the classical M1 or alternative M2 subtype. At the late stage of human cancers, most of the infiltrating macrophages display an M2 phenotype, creating an immunosuppressive microenvironment that favors tumor progression. Increased miR-21-5p delivery by MSC-derived extracellular vesicles was recently reported to promote the polarization of macrophages towards an M2 phenotype (48). miR-125b binds to the 3' untranslated region of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), inhibiting its production and sustaining an M1 phenotype (49). By contrast, miR-146 directly inhibits the expression of the adaptor protein tumor necrosis factor receptor-associated factor 6 and IL-1 receptor-associated kinase-1 in the NF- $\kappa$ B pathway, thus reducing pro-inflammatory cytokine production and promoting alternative M2 activation (5).

In addition to regulating the polarization and phenotype of TAMs, miRNAs have also been shown to regulate other functionalities of TAMs, including infiltration, immune responses and tumor-promoting effects. Ke *et al* reported that low miR-148b levels in hepatocellular carcinoma (HCC) cells enhanced the expression of colony-stimulating factor-1, promoting TAM infiltration and HCC metastasis (50). Moreover, another crucial miRNA involved in the modulation of immune responses is miR-155, which is persistently

Table I. MicroRNAs in tumor microenvironment remodeling.

| MicroRNAs                                   | Cancers                  | Function   | (Refs.) |
|---|--------------------------|--|---------|
| <b>Regulation of CAFs</b>                   |                          |  |         |
| miR-9                                       | Breast cancer            | Enhancing the switch to CAF phenotype  | (29)    |
| miR-200s                                    | Breast cancer            | Inhibiting CAF activation by targeting Fli-1 and TCF12   | (31)    |
| miR-205                                     | Breast cancer            | Inhibiting the switch to CAFs by regulating YAP1   | (34)    |
| miR-155                                     | Ovarian cancer           | Promoting conversion of the fibroblasts to a CAF-like  | (30,32) |
|   | Pancreatic cancer        | phenotype by targeting TP53INP1  |         |
| miR-214                                     | Ovarian cancer           | Inhibiting CAF activation by targeting CCL5  | (30)    |
| miR-211                                     | Melanoma                 | Enhancing the switch to CAF phenotype by targeting IGF2R and leading to MAPK signaling activation                            | (33)    |
| miR-1, miR-206, miR-31                      | Lung cancer              | Reprogramming NF-CAF conversion via affecting CCL2/VEGFA expression  | (34)    |
| <b>Regulation of cancer-associated MSCs</b> |                          |  |         |
| miR-155-5p                                  | Gastric cancer           | Inhibiting the conversion of BM-MSCs to GC-MSCs by targeting NF- $\kappa$ B p65  | (35)    |
| miR-221                                     | Gastric cancer           | Playing a tumor-supporting role  | (24)    |
| Let-7                                       | Prostate cancer          | Inhibiting the adipogenic differentiation and metastasis-promoting activity of cancer-associated MSCs by targeting IL-6      | (36)    |
| miR-146a                                    | Myeloma                  | Inducing cytokine and chemokine secretion in MSCs  | (37)    |
| miR-7977                                    | Myeloid neoplasms        | Decreasing hematopoiesis-supporting capacity of bone marrow CD34 <sup>+</sup> cells.   | (38)    |
| <b>Regulation of TAM</b>                    |                          |  |         |
| miR-125b                                    | Lymphoma                 | Enhancing macrophage responsiveness to IFN $\gamma$ and increasing surface expression of its cognate receptor                | (45)    |
| miR-155                                     | Gastric cancer           | Suppressing cytokine production in tumor-activated monocytes/macrophages by targeting C/EBP $\beta$                          | (46)    |
| miR-511-3p                                  | Lung cancer              | Inhibiting the tumor-promoting functions of TAMs   | (49)    |
| miR-21, miR-29a                             | Lung cancer              | Inducing the secretion of the proinflammatory cytokines TNF- $\alpha$ and IL-6 by TLR8-mediated activation of NF- $\kappa$ B | (50)    |
| miR-21-5p                                   | Lung cancer              | Promoting the polarization of M2 macrophages   | (48)    |
| miR-148b                                    | Hepatocellular carcinoma | Inhibiting TAM infiltration and HCC metastasis by downregulating the colony stimulating factor-1 expression                  | (50)    |
| <b>Regulation of T cells</b>                |                          |  |         |
| miR-24-3p                                   | Nasopharyngeal carcinoma | Inducing differentiation of Tregs by targeting FGF11   | (53)    |
| miR-214                                     | Lung cancer              | Inducing the secretion of IL-10 from Tregs and modulating Treg induction   | (52)    |
| miR-21                                      | Breast cancer            | Reducing the proliferation of Tregs by targeting the PTEN and Akt pathways   | (54)    |
| miR-149-3p                                  | Breast cancer            | Enhancing T-cell proliferation and activation  | (62)    |
| miR-448                                     | Colon cancer             | Suppressing the apoptosis of CD8 <sup>+</sup> T cells and enhancing CD8 <sup>+</sup> T-cell response                         | (63)    |
| <b>Regulation of endothelial cells</b>      |                          |  |         |
| miR-29a/c                                   | Gastric cancer           | Suppressing angiogenesis by targeting VEGF in the gastric tumor microenvironment.  | (57)    |
| miR-939                                     | Breast cancer            | Increasing HUVEC monolayer permeability by targeting vascular endothelial-cadherin.  | (58)    |
| miR-143/145                                 | Lung cancer              | Stimulating the proliferation of endothelial cells and regulating endothelial cell migration                                 | (60)    |

Table I. Continued.

| MicroRNAs                      | Cancers                  | Function   | (Refs.) |
|--------------------------------|--------------------------|--|---------|
| miR-125b                       | Glioblastoma             | Mediating VEGF-induced angiogenesis by targeting Myc-associated zinc finger protein  | (61)    |
| miR-93                         | Breast cancer            | Enhancing endothelial tube formation by increasing blood vessel density  | (62)    |
| miR-638                        | Hepatocellular carcinoma | Suppressing angiogenesis by inhibiting VEGF signaling  | (65)    |
| miR-205                        | Breast cancer            | Regulating YAP1-mediated IL-11 and IL-15 expression and secretion in CAFs, which enhance tubule formation                              | (34)    |
| Regulation of tumor growth     |                          |  |         |
| miR-7                          | Head and neck cancer     | CAF-mediated tumor-promoting effect by targeting RASSF2  | (67)    |
| miR-211                        | Melanoma                 | CAF-mediated tumor-promoting effect by targeting IGF2R   | (33)    |
| miR-125a                       | Lung cancer              | TAM-mediated antitumor activity by targeting FIH1 and IRF4   | (48)    |
| miR-638                        | Hepatocellular carcinoma | Angiogenesis-mediated antitumor activity by targeting VEGF   | (65)    |
| miR-143/145                    | Lung cancer              | Endothelial cell-mediated tumor-promoting effect by targeting CAMK1D   | (60)    |
| miR-3188                       | Head and neck cancer     | CAF-derived exosomal expression regulating tumor growth  | (76)    |
| miR-501-3p                     | Pancreatic ductal        | M2 macrophage-derived exosomal miR-501-3p adenocarcinoma facilitating tumor formation by regulating the TGF- $\beta$ signaling pathway | (80)    |
| Regulation of tumor metastasis |                          |  |         |
| miR-126/miR-126*               | Breast cancer            | Suppressing lung metastasis by inhibiting the recruitment of MSCs and inflammatory monocytes   | (74)    |
| miR-9                          | Breast cancer            | CAF-mediated tumor cell migration by reducing E-cadherin   | (29)    |
| miR-200s                       | Breast cancer            | CAF-mediated tumor cell invasion and metastasis by targeting Fli-1 and TCF12.  | (31)    |
| miRNA-199a                     | Breast cancer            | MSC-mediated tumor initiation and metastasis   | (75)    |
| miR-28-5p                      | Hepatocellular carcinoma | TAM-mediated metastasis by miR-28-5p-IL-34 signaling   | (76)    |
| miR-148b                       |                          | CAF-derived exosomal expression enhances tumor metastasis by targeting DNMT1   | (85)    |
| Regulation of drug resistance  |                          |  |         |
| miR-122 (MSCs)                 | Hepatocellular carcinoma | Increasing the chemosensitivity of HCC cells by negative regulation of CCNG1, ADAM10 and IGF1R   | (77)    |
| miR-101 (macrophage)           | Hepatocellular carcinoma | Inhibited by sorafenib and enhancing DUSP1, leading to the inhibition of macrophage-induced HCC growth                                 | (78)    |
| miR-21 (macrophage)            | Gastric cancer           | Reducing the sensitivity of gastric cancer cells to cisplatin through the regulation of PTEN/PI3K/AKT                                  | (79)    |

downregulated in TAMs (51,52). Soluble factors in HCC can downregulate miR-155 in TAMs. When the expression of miR-155 is restored in macrophages, both direct and indirect antitumor responses are promoted through the enhancement of T-cell function (51). Using a transgenic mouse model, Zhao *et al* demonstrated that miR-125a, a

downstream molecule of Notch signaling pathway, could reprogram macrophages in the TME and restore their anti-tumor potential by targeting certain factors, including factor inhibiting hypoxia-inducible factor-1, interferon regulatory factor 4, and RING1- and YY1-binding protein (53). A recent report indicated that miR-511-3p exerted regulatory effects on






Figure 1. MicroRNAs in tumor microenvironment remodeling. The tumor microenvironment consists of CAFs, immune cells (such as Tregs and TAMs), endothelial cells, MSCs and ECM. The aberrant expression of miRNAs in tumor microenvironment could control cell differentiation, cell activation, and secretion of cytokines and chemokines, which eventually affects the process of tumor progression. CAFs, cancer-associated fibroblasts; Tregs, regulatory T cells; TAMs, tumor-associated macrophages; MSCs, mesenchymal stem cells; ECM, extracellular matrix.

TAMs, and that miR-511-3p overexpression in TAMs inhibited tumor growth *in vivo*, suggesting that miR-511-3p limits the tumor-promoting function of TAMs (54). miR-21 and miR-29a are delivered from cancer cells to macrophages via microvesicles and subsequently bind to intracellular toll-like receptors (TLR7 or TLR8). This miRNA-TLR interaction results in the activation of the NF- $\kappa$ B pathway and increased production of the pro-inflammatory cytokines IL-6 and TNF- $\alpha$  in TAMs, which in turn promotes cancer metastasis (55). Unexpectedly, apoptotic breast cancer cell-derived miR-375, which is released as a non-exosome entity, is taken up by macrophages via the CD36 receptor and enhances the migration and infiltration of macrophages towards tumor spheroids by targeting tensin 3 and paxillin (56). Therefore, the miRNAs of TME play a key role in regulating the phenotype and function of TAMs through several pathways.

**Role of miRNAs in regulating T cells.** miRNAs play a key role in T-cell maturation, activation and function. The immunosuppressive FOXP3<sup>+</sup> regulatory T cells (Tregs) are enriched in tumor tissues and are associated with cancer development and progression (57,58). Exosomal miR-24-3p inhibits T-cell proliferation and Th1 and Th17 differentiation, and promotes Treg development through the repression of fibroblast growth factor 11 (59). Tumor-secreted miR-214 can induce Tregs to

secrete higher levels of IL-10 by downregulating *PTEN*, leading to immune suppression and rapid tumor growth. The inhibition of cancer cell-secreted miR-214 has been shown to block Treg induction and tumor growth, suggesting that anti-miR-214 therapy can abolish tumor-induced Treg expansion and suppress tumor growth (58). The silencing of miR-21 has been reported to significantly reduce the proliferation of chemokine receptor 6-positive Tregs by targeting *PTEN* and the subsequently activated Akt pathway, which is crucial for the induction and functional sustainability of CD4<sup>+</sup> FOXP3<sup>+</sup> Tregs (60). miR-126 silencing was also shown to impair the expression of *FOXP3* and inhibit the expression of functional molecules in Tregs.

Moreover, in a murine mammary cancer model, the silencing of miR-126 in Tregs resulted in enhanced antitumor activity of CD8<sup>+</sup> T cells (61). Additionally, miR-149-3p was found to enhance T-cell proliferation and secretion of cytokines, indicative of increased T-cell activation, which may reverse CD8<sup>+</sup> T-cell exhaustion and promote CD8<sup>+</sup> T-cell-mediated killing of 4T1 mouse breast tumor cells (62). Notably, in human colon cancer, miR-448 could also suppress CD8<sup>+</sup> T-cell apoptosis and enhance CD8<sup>+</sup> T-cell response by inhibiting indoleamine 2,3-dioxygenase 1 enzyme function (63). These results suggest that miRNAs are key regulators of the functions of T cells in the TME.

**Role of miRNAs in regulating endothelial cells.** Angiogenesis is crucial for tumor progression and metastasis. Mangala *et al* isolated endothelial cells from high-grade serous ovarian cancer and normal ovarian tissues and identified deregulated miRNAs in cancer-associated endothelial cells (64); they demonstrated that one of the deregulated miRNAs, miR-29a/c, was a regulator of VEGF. The downregulation of miR-29a/c was shown to promote GC progression by increasing VEGF expression (65). In breast cancer, tumor cells can release miR-939 to endothelial cells via exosomes, and miR-939 was shown to suppress the expression of its target gene vascular endothelial-cadherin in endothelial cells, increasing vascular permeability (66). Moreover, miR-205 suppression in other cells of the TME, including CAFs, was reported to enhance tubule formation and sprouting of endothelial cells by regulating YAP1-mediated IL-11 and IL-15 expression and secretion (34). In prostate cancer, miR-218 downregulation was shown to promote tumor angiogenesis through the regulatory-associated protein-independent companion of mammalian target of rapamycin complex 2/VEGFA axis (67). In lung cancer, miR-143/145 markedly promotes tumor growth by stimulating the proliferation of endothelial cells (68). In glioma, the downregulation of miR-125b may inhibit the expression of Myc-associated zinc finger protein, thereby attenuating primary human brain endothelial cell migration and tubule formation *in vitro* (69). The upregulation of miR-93 was reported to enhance tumor growth via integrin- $\beta$ 8-mediated angiogenesis (70), as well as to enhance endothelial tube formation and increase blood vessel density *in vivo* (71). The downregulation of miR-29b was also shown to promote VEGFR signaling in endothelial cells, enhancing angiogenesis (72). Another miRNA involved in angiogenesis is miR-638, which was shown to suppress HCC growth by inhibiting VEGF signaling (73). These findings demonstrate that miRNAs play diverse roles in regulating endothelial cell activity and tumor angiogenesis.

### 3. Role of TME-derived miRNAs in regulating tumor progression

**TME-associated miRNAs in regulating tumor growth.** Tumor growth is highly dependent on the communication between tumor cells and cells of the TME. During tumor progression, miRNAs participate in the intricate interactions between tumor cells and tumor stromal cells, such as CAFs, endothelial cells and infiltrating immune cells. For example, fibroblasts provide a stromal framework for tumor cells during early tumor growth (29,74). Recent studies have revealed that the upregulated miR-7 suppresses RAS-association domain family member 2 expression in CAFs, which in turn enhances the proliferation of head and neck cancer cells (75). Wang *et al* also observed that loss of CAF-derived exosomal miR-3188 may affect the proliferation and apoptosis of tumor cells (76). Melanoma cell-derived miR-211 was shown to induce CAF formation by directly targeting insulin-like growth factor 2 and activating mitogen-activated protein kinase signaling, which in turn enhances the growth of melanoma (36). TAMs play pivotal roles in tumor growth (77-79). Yin *et al* reported that M2 macrophage-derived exosomal miR-501-3p facilitated tumor formation *in vivo* via regulating the transforming growth

factor (TGF)- $\beta$  signaling pathway (80). Macrophages transfected with a miR-125a mimic exhibited increased phagocytic activity and repressed lung cancer growth in mice (53).

Additionally, the increased levels of miR-27a inhibited dendritic cell-mediated differentiation of Th1 and Th17 cells and enhanced the growth of melanoma cells (81). The downregulation of miR-638 was demonstrated to promote angiogenesis and HCC growth by targeting VEGF, whereas its overexpression inhibited tumor angiogenesis (73). miR-143/145 in the lung cancer microenvironment markedly promoted tumor growth by targeting calcium/calmodulin-dependent protein kinase 1D, an inhibitory kinase, the overexpression of which prevents the mitotic entry of endothelial cells (68). Thus, TME-associated miRNAs play key roles in tumor growth.

**Role of TME-associated miRNAs in regulating tumor metastasis.** Metastasis accounts for ~90% of cancer-related deaths (82,83). The metastatic ability of tumor cells is enhanced by their interactions with tumor stromal cells. miRNAs participate in several steps of the metastatic process. In a mouse xenograft model, miR-126/miR-126\* independently inhibited the sequential recruitment of MSCs and inflammatory monocytes into the tumor stroma, thus suppressing lung metastasis through the downregulation of stromal cell-derived factor-1  $\alpha$  and CCL2 (84). Tumor-secreted miR-9 may be transferred via exosomes to the recipient NFs, and miR-9, in turn, is secreted by fibroblasts to stimulate breast cancer cell migration through the reduction of E-cadherin (31). Recently, low levels of miR-200s in CAFs were found to increase Fli-1 and TCF12 expression and promote stromal ECM remodeling to drive tumor metastasis through the upregulation of fibronectin and lysyl oxidase in breast cancer (33). Furthermore, low-level CAF-derived exosomal miR-148b may be transferred to endometrial cancer cells and enhance endometrial cancer metastasis by targeting DNA-methyltransferase 1, which is an important regulator of tumor metastasis (85). MSC-induced expression of miRNA-199a was shown to enhance the stem cell properties of breast cancer cells, thereby promoting tumor initiation and metastasis (86). The aberrantly expressed miRNAs in TAMs also play pivotal roles in tumor metastasis. miR-28-5p deficiency was shown to upregulate the expression of IL-34 to recruit TAMs, consequently promoting tumor metastasis (87). M2 macrophage-derived exosomal miR-501-3p was found to facilitate the liver and lung metastasis of pancreatic ductal adenocarcinoma (PDAC) cells (80). In summary, miRNAs in the TME are well-established crucial mediators of tumor metastasis.

**Role of TME-associated miRNAs in regulating drug resistance.** Resistance to chemotherapy and targeted therapy is a major challenge in clinical practice. Accumulating evidence suggests that miRNAs from the TME may affect drug resistance. In HCC, exosomal miR-122 (122-Exo) from adipose tissue-derived MSCs can be delivered into HCC cells, increasing the chemosensitivity of HCC cells by inhibiting the expression of cyclin G1, a disintegrin and metalloprotease 10, and insulin-like growth factor receptor 1 (IGF1R). Intratumoral injection of 122-Exo significantly increased the antitumor efficacy of sorafenib in HCC *in vivo* (88). Moreover, the chemotherapeutic agent sorafenib can inhibit miR-101

expression and enhance dual-specificity phosphatase 1 expression, leading to the inhibition of macrophage-induced HCC growth (89). In GC, miR-21 was transferred from macrophages to GC cells via exosomes and resulted in a significant reduction in the sensitivity of GC cells to cisplatin chemotherapy *in vitro* and *in vivo*, partially through the regulation of the PTEN/phosphoinositide 3-kinase/AKT signaling pathway (90). The levels of miR-27a/b in the serum were significantly higher in patients with esophageal cancer compared with those in healthy volunteers, and high expression levels of miR-27a/b were shown to induce the transformation of NFs into CAFs through upregulation of TGF- $\beta$ , leading to chemoresistance in esophageal cancer cells (91). These results suggest that TME-derived miRNAs play a critical role in drug resistance.

#### 4. Clinical applications of tumor-associated miRNAs

*miRNAs as cancer diagnostic biomarkers.* miRNAs have exhibited great potential in cancer diagnosis and prognosis. Circulating miRNAs in body fluids, such as plasma, serum and urine, have high diagnostic potential as cancer biomarkers due to their combination with argonaute protein or high-density lipoprotein, which protects them from degradation by extreme pH, high temperature and RNase. The vast majority of studies conducted thus far have focused on miRNAs in the tumor cells or the TME. Bryant *et al* reported that miR-107 and miR-574-3p were present at higher concentrations in the urine of men with prostate cancer compared with healthy individuals, indicating their potential as non-invasive biomarkers (92). Lee *et al* reported that circulating miR-146b and miR-155 levels were significantly higher in patients with papillary thyroid carcinoma compared with those with benign tumors. The levels of miR-146b and miR-155 were also positively associated with tumor size (93).

Moreover, Yi *et al* identified circulating miR-31-5p as a potentially novel and non-invasive biomarker for the early diagnosis of nasopharyngeal carcinoma (94). Nobuyoshi *et al* observed higher miR-92 levels in patients with colorectal cancer compared with those patients with inflammatory bowel diseases or in healthy volunteers; hence, it may be used as a biomarker to detect colorectal cancer (95). Few studies have explored the diagnostic potential of TME-derived miRNAs. In acute myeloid leukemia (AML), bone marrow stromal cell-derived miRNAs, including miR-150, -155 and -1246, were present in serum exosomes and were able to improve the sensitivity and specificity for detecting residual or recurrent AML, thereby providing a reliable cell-free marker that is unaffected by chemotherapy (96). We also previously demonstrated that miR-221 was highly expressed in MSCs from human GC tissues. The expression of MSC-derived miR-221 was positively associated with the proliferation and migration of GC cells, suggesting that it may be a new potential biomarker for GC diagnosis (26). In breast cancer, the expression of miR-21 in CCR6-expressing Tregs is very high, whereas silencing of miR-21 enhances the expression of *PTEN*, which inhibits the proliferation of Tregs in the tumor tissues and endows CD8<sup>+</sup> T cells with effective antitumor functions, indicating a new biomarker for breast cancer prognosis (60). In PDAC, the strong expression of miR-21 in CAFs was found to be associated with decreased overall survival in PDAC patients receiving 5-fluorouracil, but not gemcitabine. Thus, miR-21 may serve as a marker

to guide chemotherapy options in PDAC patients (97). However, the number of TME-associated miRNAs identified as cancer biomarkers is currently limited and further research is required.

*miRNAs in cancer therapy.* According to the literature, miRNA-based antitumor therapy can be broadly divided into two distinct approaches, namely miRNA silencing by anti-miRNAs and miRNA restoration. Cubillos-Ruiz *et al* reported that nanoparticles carrying oligonucleotide duplexes markedly augmented miR-155 activity and transformed tumor-associated dendritic cells from the immunosuppressive phenotype to highly immunostimulatory cells, eliciting potent antitumor responses that eliminate ovarian cancer cells (98). In a mouse breast cancer model, let-7b delivered through a nucleic acid delivery system expeditiously reprogrammed the functions of TAMs and tumor-infiltrating dendritic cells, leading to the inhibition of tumor growth. This strategy may represent a new approach to cancer immunotherapy (99). Additionally, miR-21 depletion in TAMs promoted tumoricidal M1 polarization by upregulating Janus kinase 2 and Signal transducer and activator of transcription 1, and this, combined with programmed cell death protein 1 blockade, may exert synergistic effects and exhibit superior antitumor activity (100).

Moreover, the targeted interference of deregulated miRNAs in cancer-associated endothelial cells was shown to decrease vascular permeability. Pi *et al* reported that the elevated expression of miR-302/367 significantly suppressed tumor growth by restricting sprout angiogenesis and decreasing vascular permeability (101). Schnittert *et al* reported that anti-miR-199a, delivered via peptide-based nanocomplexes, may inhibit human-derived pancreatic stellate cell (hPSC) differentiation into CAFs and repress the size of 3D heterospheroids, which consist of hPSCs and tumor cells (102). In summary, targeting miRNAs has emerged as a novel, promising approach to cancer treatment.

#### 5. Conclusion

The present review summarized the roles of miRNAs in the communication between tumor cells and tumor stromal cells. Deregulated expression of several miRNAs has been observed in both types of cells, clearly highlighting the crucial roles of miRNAs in cancer development and progression (Fig. 1; Table I). Numerous examples in which miRNAs were demonstrated to regulate the critical aspects of TME involved in tumor angiogenesis, tumor cell growth and metastasis were herein summarized. Previous studies elucidated some of the mechanisms by which these small RNAs in the TME considerably affect tumor biology. Undoubtedly, miRNA-related research has great potential for the identification of important biomarkers and for promoting the development of novel cancer therapies. As it has been reported in previous studies, miRNA delivery to tumors is an attractive yet challenging opportunity to improve therapeutic strategies for cancer (103,104). However, more cancer-related pathways must be identified as specific targets of miRNAs, and additional efforts are required to ultimately design an optimal delivery system for miRNAs. Several novel siRNA and miRNA delivery systems are currently under development. However, despite the enormous



potential of microRNAs in cancer diagnosis and anticancer clinical practice, microRNAs are not yet widely applied as cancer biomarkers and therapy targets in the clinical setting, as numerous obstacles must be overcome before their widespread application.

### Acknowledgements

The authors would like to thank Wenrong Xu and Xu Zhang (Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China) for their ideas and support.

### Funding

The present study was supported by the Special Foundation for Young Scientists of Jiangsu Province (grant no. QNRC2016379), Xuzhou Central Hospital and Xinyi People's Hospital.

### Availability of data and materials

The datasets used and analyzed during the present study are available from the corresponding author on reasonable request.

### Authors' contributions

ZP and YT made substantial contributions to conception and design and wrote the manuscript. GN and CC critically revised the manuscript for important intellectual content. ZP, YT, GN and CC reviewed and edited the manuscript. All authors have read and approved the final version of the manuscript for publication.

### Ethics approval and consent to participate

Not applicable.

### Patient consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### References

- Naito Y, Yoshioka Y, Yamamoto Y and Ochiya T: How cancer cells dictate their microenvironment: Present roles of extracellular vesicles. *Cell Mol Life Sci* 74: 697-713, 2017.
- Dachs GU and Chaplin DJ: Microenvironmental control of gene expression: Implications for tumor angiogenesis, progression, and metastasis. *Semin Radiat Oncol* 8: 208-216, 1998.
- Whiteside TL: Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment. *Semin Immunol* 35: 69-79, 2018.
- Quail DF and Joyce JA: Microenvironmental regulation of tumor progression and metastasis. *Nat Med* 19: 1423-1437, 2013.
- Chou J, Shahi P and Werb Z: microRNA-mediated regulation of the tumor microenvironment. *Cell Cycle* 12: 3262-3271, 2013.
- Li X, Wu Z, Fu X and Han W: A microRNA component of the neoplastic Microenvironment: microregulators with far-reaching impact. *Biomed Res Int* 2013: 762183, 2013.
- Zhang Y, Yang P and Wang XF: Microenvironmental regulation of cancer metastasis by miRNAs. *Trends Cell Biol* 24: 153-160, 2014.
- Xu SJ, Hu HT, Li HL and Chang S: The role of miRNAs in immune cell development, immune cell activation, and tumor immunity: With a focus on macrophages and natural killer cells. *Cells* 8: pii: E1140, 2019.
- Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Sacca M, Memeo L, Colarossi C, Francescangeli F, Biffoni M, Collura D, *et al*: Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. *Oncogene* 30: 4231-4242, 2011.
- Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO Mol Med* 9: 852, 2017.
- Que KT, Zhou Y, You Y, Zhang Z, Zhao XP, Gong JP and Liu ZJ: MicroRNA-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma. *J Exp Clin Cancer Res* 37: 268, 2018.
- Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, *et al*: A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 103: 2257-2261, 2006.
- Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. *Oncogene* 27: 2128-2136, 2008.
- Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A and Lund AH: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. *J Biol Chem* 283: 1026-1033, 2008.
- He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, *et al*: A microRNA component of the p53 tumour suppressor network. *Nature* 447: 1130-1134, 2007.
- Corsini LR, Bronte G, Terrasi M, Amodeo V, Fanale D, Fiorentino E, Cicero G, Bazan V and Russo A: The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies. *Expert Opin Ther Targets* 16 (Suppl 2): S103-S109, 2012.
- Nana-Sinkam SP and Croce CM: Clinical applications for microRNAs in cancer. *Clin Pharmacol Ther* 93: 98-104, 2013.
- Pichler M and Calin GA: MicroRNAs in cancer: From developmental genes in worms to their clinical application in patients. *Br J Cancer* 113: 569-573, 2015.
- Soon P and Kiaris H: MicroRNAs in the tumour microenvironment: Big role for small players. *Endocr Relat Cancer* 20: R257-R267, 2013.
- Rupaimoole R, Calin GA, Lopez-Berestein G and Sood AK: miRNA deregulation in cancer cells and the tumor microenvironment. *Cancer Discov* 6: 235-246, 2016.
- Kuninty PR, Schnittert J, Storm G and Prakash J: MicroRNA targeting to modulate tumor microenvironment. *Front Oncol* 6: 3, 2016.
- Fanini F and Fabbri M: Cancer-derived exosomal microRNAs shape the immune system within the tumor microenvironment: State of the art. *Semin Cell Dev Biol* 67: 23-28, 2017.
- Curtale G: MiRNAs at the crossroads between innate immunity and cancer: Focus on macrophages. *Cells* 7: pii: E12, 2018.
- Bandini E, Rossi T, Gallerani G and Fabbri F: Adipocytes and microRNAs crosstalk: A key tile in the mosaic of breast cancer microenvironment. *Cancers (Basel)* 11: pii: E1451, 2019.
- Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM, Risinger JI, Jazaeri A and Niederhuber J: The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. *Cell Cycle* 9: 4387-4398, 2010.
- Wang M, Zhao C, Shi H, Zhang B, Zhang L, Zhang X, Wang S, Wu X, Yang T, Huang F, *et al*: Deregulated microRNAs in gastric cancer tissue-derived mesenchymal stem cells: Novel biomarkers and a mechanism for gastric cancer. *Br J Cancer* 110: 1199-1210, 2014.
- Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F, Wang X, Wang J, Yu H, Cao X and Wang Q: MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. *J Immunol* 188: 5500-5510, 2012.
- Erez N, Truitt M, Olson P, Arron ST and Hanahan D: Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. *Cancer Cell* 17: 135-147, 2010.
- Kalluri R and Zeisberg M: Fibroblasts in cancer. *Nat Rev Cancer* 6: 392-401, 2006.



30. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathysaraja H, Srinivasan R, Trimboli AJ, Martin CK, Li F, *et al*: Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. *Nat Cell Biol* 14: 159-167, 2011.
31. Baroni S, Romero-Cordoba S, Plantamura I, Dugo M, D'Ipollito E, Cataldo A, Cosentino G, Angeloni V, Rossini A, Daidone MG and Iorio MV: Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. *Cell Death Dis* 7: e2312, 2016.
32. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murrmann AE, Peter ME and Lengyel E: MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. *Cancer Discov* 2: 1100-1108, 2012.
33. Tang X, Hou Y, Yang G, Wang X, Tang S, Du YE, Yang L, Yu T, Zhang H, Zhou M, *et al*: Stromal miR-200s contribute to breast cancer cell invasion through CAF activation and ECM remodeling. *Cell Death Differ* 23: 132-145, 2016.
34. Du YE, Tu G, Yang G, Li G, Yang D, Lang L, Xi L, Sun K, Chen Y, Shu K, *et al*: MiR-205/YAP1 in activated fibroblasts of breast tumor promotes VEGF-independent angiogenesis through STAT3 signaling. *Theranostics* 7: 3972-3988, 2017.
35. Pang W, Su J, Wang Y, Feng H, Dai X, Yuan Y, Chen X and Yao W: Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts. *Cancer Sci* 106: 1362-1369, 2015.
36. Dror S, Sander L, Schwartz H, Sheinboim D, Barzilai A, Dishon Y, Apcher S, Golan T, Greenberger S, Barshack I, *et al*: Melanoma miRNA trafficking controls tumour primary niche formation. *Nat Cell Biol* 18: 1006-1017, 2016.
37. Shen H, Yu X, Yang F, Zhang Z, Shen J, Sun J, Choksi S, Jitkaew S and Shu Y: Reprogramming of normal fibroblasts into cancer-associated fibroblasts by miRNAs-mediated CCL2/VEGFA signaling. *PLoS Genet* 12: e1006244, 2016.
38. Zhu M, Wang M, Yang F, Tian Y, Cai J, Yang H, Fu H, Mao F, Zhu W, Qian H and Xu W: miR-155-5p inhibition promotes the transition of bone marrow mesenchymal stem cells to gastric cancer tissue derived MSC-like cells via NF- $\kappa$ B p65 activation. *Oncotarget* 7: 16567-16580, 2016.
39. Sung SY, Liao CH, Wu HP, Hsiao WC, Wu IH, Jinpu, Yu, Lin SH and Hsieh CL: Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. *PLoS One* 8: e71637, 2013.
40. De Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E and Van Riet I: Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. *Cancer Lett* 377: 17-24, 2016.
41. Horiguchi H, Kobune M, Kikuchi S, Yoshida M, Murata M, Murase K, Iyama S, Takada K, Sato T, Ono K, *et al*: Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms. *Haematologica* 101: 437-447, 2016.
42. Jang JY, Lee JK, Jeon YK and Kim CW: Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization. *BMC Cancer* 13: 421, 2013.
43. Xu Z, Zhao L, Zhu LY, He M, Zheng L and Wu Y: MicroRNA-17, 20a regulates the proangiogenic function of tumor-associated macrophages via targeting hypoxia-inducible factor 2 $\alpha$ . *PLoS One* 8: e77890, 2013.
44. Lagrange B, Martin RZ, Droin N, Aucagne R, Paggetti J, Largeot A, Itzykson R, Solary E, Delva L and Bastie JN: A role for miR-142-3p in colony-stimulating factor 1-induced monocyte differentiation into macrophages. *Biochim Biophys Acta* 1833: 1936-1946, 2013.
45. Baj-Krzyworzeka M, Mytar B, Szatanek R, Surmiak M, Węglarczyk K, Baran J and Siedlar M: Colorectal cancer-derived microvesicles modulate differentiation of human monocytes to macrophages. *J Transl Med* 14: 36, 2016.
46. Li Y, Zhao L, Shi B, Ma S, Xu Z, Ge Y, Liu Y, Zheng D and Shi J: Functions of miR-146a and miR-222 in tumor-associated macrophages in breast cancer. *Sci Rep* 5: 18648, 2015.
47. Huber V, Vallacchi V, Fleming V, Hu X, Cova A, Dugo M, Shahaj E, Sulsenti R, Vergani E, Filipazzi P, *et al*: Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. *J Clin Invest* 128: 5505-5516, 2018.
48. Ren W, Hou J, Yang C, Wang H, Wu S, Wu Y, Zhao X and Lu C: Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery. *J Exp Clin Cancer Res* 38: 62, 2019.
49. Chaudhuri AA, So AY, Sinha N, Gibson WS, Taganov KD, O'Connell RM and Baltimore D: MicroRNA-125b potentiates macrophage activation. *J Immunol* 187: 5062-5068, 2011.
50. Ke M, Zhang Z, Cong L, Zhao S, Li Y, Wang X, Lv Y, Zhu Y and Dong J: MicroRNA-148b-colony-stimulating factor-1 signaling-induced tumor-associated macrophage infiltration promotes hepatocellular carcinoma metastasis. *Biomed Pharmacother* 120: 109523, 2019.
51. He M, Xu Z, Ding T, Kuang DM and Zheng L: MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBP $\beta$ . *Cell Mol Immunol* 6: 343-352, 2009.
52. Zonari E, Pucci F, Saini M, Mazziere R, Politi LS, Gentner B and Naldini L: A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. *Blood* 122: 243-252, 2013.
53. Zhao JL, Huang F, He F, Gao CC, Liang SQ, Ma PF, Dong GY, Han H and Qin HY: Forced activation of notch in macrophages represses tumor growth by upregulating miR-125a and disabling tumor-associated macrophages. *Cancer Res* 76: 1403-1415, 2016.
54. Squadrito ML, Pucci F, Magri L, Moi D, Gilfillan GD, Ranghetti A, Casazza A, Mazzone M, Lyle R, Naldini L and De Palma M: miR-511-3p modulates genetic programs of tumor-associated macrophages. *Cell Rep* 1: 141-154, 2012.
55. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, *et al*: MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. *Proc Natl Acad Sci USA* 109: E2110-2116, 2012.
56. Frank AC, Ebersberger S, Fink AF, Lampe S, Weigert A, Schmid T, Ebersberger I, Syed SN and Brüne B: Apoptotic tumor cell-derived microRNA-375 uses CD36 to alter the tumor-associated macrophage phenotype. *Nat Commun* 10: 1135, 2019.
57. Xu L, Xu W, Wen Z and Xiong S: In situ prior proliferation of CD4+ CCR6+ regulatory T cells facilitated by TGF- $\beta$  secreting DCs is crucial for their enrichment and suppression in tumor immunity. *PLoS One* 6: e20282, 2011.
58. Yin Y, Cai X, Chen X, Liang H, Zhang Y, Li J, Wang Z, Chen X, Zhang W, Yokoyama S, *et al*: Tumor-secreted miR-214 induces regulatory T cells: A major link between immune evasion and tumor growth. *Cell Res* 24: 1164-1180, 2014.
59. Ye SB, Zhang H, Cai TT, Liu YN, Ni JJ, He J, Peng JY, Chen QY, Mo HY, Jun-Cui, *et al*: Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma. *J Pathol* 240: 329-340, 2016.
60. Hu Y, Wang C, Li Y, Zhao J, Chen C, Zhou Y, Tao Y, Guo M, Qin N, Ren T, *et al*: MiR-21 controls in situ expansion of CCR6+ regulatory T cells through PTEN/AKT pathway in breast cancer. *Immunol Cell Biol* 93: 753-764, 2015.
61. Qin A, Wen Z, Zhou Y, Li Y, Li Y, Luo J, Ren T and Xu L: MicroRNA-126 regulates the induction and function of CD4(+) Foxp3(+) regulatory T cells through PI3K/AKT pathway. *J Cell Mol Med* 17: 252-264, 2013.
62. Zhang M, Gao D, Shi Y, Wang Y, Joshi R, Yu Q, Liu D, Alotaibi F, Zhang Y, Wang H, *et al*: miR-149-3p reverses CD8+ T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells. *Open Biol* 9: 190061, 2019.
63. Lou Q, Liu R, Yang X, Li W, Huang L, Wei L, Tan H, Xiang N, Chan K, Chen J and Liu H: miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer. *J Immunother Cancer* 7: 210, 2019.
64. Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, *et al*: Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. *JCI Insight* 3: pii: 122387, 2018.
65. Zhang H, Bai M, Deng T, Liu R, Wang X, Qu Y, Duan J, Zhang L, Ning T, Ge S, *et al*: Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma. *Cancer Lett* 375: 331-339, 2016.
66. Di Modica M, Regondi V, Sandri M, Iorio MV, Zanetti A, Tagliabue E, Casalini P and Triulzi T: Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. *Cancer Lett* 384: 94-100, 2017.
67. Guan B, Wu K, Zeng J, Xu S, Mu L, Gao Y, Wang K, Ma Z, Tian J, Shi Q, *et al*: Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer. *Oncotarget* 8: 8162-8172, 2017.
68. Dimitrova N, Gocheva V, Bhutkar A, Resnick R, Jong RM, Miller KM, Bendor J and Jacks T: Stromal expression of miR-143/145 promotes neoangiogenesis in lung cancer development. *Cancer Discov* 6: 188-201, 2016.

69. Smits M, Wurdinger T, van het Hof B, Drexhage JA, Geerts D, Wesseling P, Noske DP, Vandertop WP, de Vries HE and Reijerkerk A: Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma. *FASEB J* 26: 2639-2647, 2012.
70. Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, Yee AJ, Ang LC, He C, Shan SW and Yang BB: MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin- $\beta$ 8. *Oncogene* 30: 806-821, 2011.
71. Fang L, Du WW, Yang W, Rutnam ZJ, Peng C, Li H, O'Malley YQ, Askeland RW, Sugg S, Liu M, *et al*: MiR-93 enhances angiogenesis and metastasis by targeting LATS2. *Cell Cycle* 11: 4352-4365, 2012.
72. Szczyrba J, Nolte E, Hart M, Döll C, Wach S, Taubert H, Keck B, Kremmer E, Stöhr R, Hartmann A, *et al*: Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. *Int J Cancer* 132: 775-784, 2013.
73. Cheng J, Chen Y, Zhao P, Liu X, Dong J, Li J, Huang C, Wu R and Lv Y: Downregulation of miRNA-638 promotes angiogenesis and growth of hepatocellular carcinoma by targeting VEGF. *Oncotarget* 7: 30702-30711, 2016.
74. Schauer IG, Sood AK, Mok S and Liu J: Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. *Neoplasia* 13: 393-405, 2011.
75. Shen Z, Qin X, Yan M, Li R, Chen G, Zhang J and Chen W: Cancer-associated fibroblasts promote cancer cell growth through a miR-7-RASSF2-PAR-4 axis in the tumor microenvironment. *Oncotarget* 8: 1290-1303, 2017.
76. Wang X, Qin X, Yan M, Shi J, Xu Q, Li Z, Yang W, Zhang J and Chen W: Loss of exosomal miR-3188 in cancer-associated fibroblasts contributes to HNC progression. *J Exp Clin Cancer Res* 38: 151, 2019.
77. Biswas SK, Allavena P and Mantovani A: Tumor-associated macrophages: Functional diversity, clinical significance, and open questions. *Semin Immunopathol* 35: 585-600, 2013.
78. De Palma M and Lewis CE: Macrophage regulation of tumor responses to anticancer therapies. *Cancer Cell* 23: 277-286, 2013.
79. Epelman S, Lavine KJ and Randolph GJ: Origin and functions of tissue macrophages. *Immunity* 41: 21-35, 2014.
80. Yin Z, Ma T, Huang B, Lin L, Zhou Y, Yan J, Zou Y and Chen S: Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF- $\beta$  signaling pathway. *J Exp Clin Cancer Res* 38: 310, 2019.
81. Min S, Li L, Zhang M, Zhang Y, Liang X, Xie Y, He Q, Li Y, Sun J, Liu Q, *et al*: TGF- $\beta$ -associated miR-27a inhibits dendritic cell-mediated differentiation of Th1 and Th17 cells by TAB3, p38 MAPK, MAP2K4 and MAP2K7. *Genes Immun* 13: 621-631, 2012.
82. Nguyen DX, Bos PD and Massague J: Metastasis: From dissemination to organ-specific colonization. *Nat Rev Cancer* 9: 274-284, 2009.
83. Valastyan S and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. *Cell* 147: 275-292, 2011.
84. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, *et al*: miR-126 and miR-126\* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. *Nat Cell Biol* 15: 284-294, 2013.
85. Li BL, Lu W, Qu JJ, Ye L, Du GQ and Wan XP: Loss of exosomal miR-148b from cancer-associated fibroblasts promotes endometrial cancer cell invasion and cancer metastasis. *J Cell Physiol* 234: 2943-2953, 2019.
86. Cuiffo BG, Campagne A, Bell GW, Lembo A, Orso F, Lien EC, Bhasin MK, Raimo M, Hanson SE, Marusyk A, *et al*: MSC-regulated microRNAs converge on the transcription factor FOXF2 and promote breast cancer metastasis. *Cell Stem Cell* 15: 762-774, 2014.
87. Zhou SL, Hu ZQ, Zhou ZJ, Dai Z, Wang Z, Cao Y, Fan J, Huang XW and Zhou J: miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. *Hepatology* 63: 1560-1575, 2016.
88. Lou G, Song X, Yang F, Wu S, Wang J, Chen Z and Liu Y: Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. *J Hematol Oncol* 8: 122, 2015.
89. Wei X, Tang C, Lu X, Liu R, Zhou M, He D, Zheng D, Sun C and Wu Z: MiR-101 targets DUSP1 to regulate the TGF- $\beta$  secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma. *Oncotarget* 6: 18389-18405, 2015.
90. Zheng P, Chen L, Yuan X, Luo Q, Liu Y, Xie G, Ma Y and Shen L: Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. *J Exp Clin Cancer Res* 36: 53, 2017.
91. Tanaka K, Miyata H, Sugimura K, Fukuda S, Kanemura T, Yamashita K, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M, *et al*: miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. *Carcinogenesis* 36: 894-903, 2015.
92. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhee B, Kuslich C, Visakorpi T and Hamdy FC: Changes in circulating microRNA levels associated with prostate cancer. *Br J Cancer* 106: 768-774, 2012.
93. Lee YS, Lim YS, Lee JC, Wang SG, Park HY, Kim SY and Lee BJ: Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer. *Oral Oncol* 51: 77-83, 2015.
94. Yi SJ, Liu P, Chen BL, Ou-Yang L, Xiong WM and Su JP: Circulating miR-31-5p may be a potential diagnostic biomarker in nasopharyngeal carcinoma. *Neoplasia* 66: 825-829, 2019.
95. Kosaka N, Iguchi H and Ochiya T: Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. *Cancer Sci* 101: 2087-2092, 2010.
96. Hornick NI, Huan J, Doron B, Goloviznina NA, Lapidus J, Chang BH and Kurre P: Serum exosome MicroRNA as a minimally-invasive early biomarker of AML. *Sci Rep* 5: 11295, 2015.
97. Donahue TR, Nguyen AH, Moughan J, Li L, Tatishchev S, Toste P and Farrell JJ: Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer. *J Surg Oncol* 110: 952-959, 2014.
98. Cubillos-Ruiz JR, Baird JR, Tesone AJ, Rutkowski MR, Scarlett UK, Camposeco-Jacobs AL, Anadon-Arnillas J, Harwood NM, Korc M, Fiering SN, *et al*: Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. *Cancer Res* 72: 1683-1693, 2012.
99. Huang Z, Gan J, Long Z, Guo G, Shi X, Wang C, Zang Y, Ding Z, Chen J, Zhang J and Dong L: Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection. *Biomaterials* 90: 72-84, 2016.
100. Xi J, Huang Q, Wang L, Ma X, Deng Q, Kumar M, Zhou Z, Li L, Zeng Z, Young KH, *et al*: miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. *Oncogene* 37: 3151-3165, 2018.
101. Pi J, Tao T, Zhuang T, Sun H, Chen X, Liu J, Cheng Y, Yu Z, Zhu HH, Gao WQ, *et al*: A MicroRNA302-367-Erk1/2-Klf2-S1 prl pathway prevents tumor growth via restricting angiogenesis and improving vascular stability. *Circ Res* 120: 85-98, 2017.
102. Schnittert J, Kuninty PR, Bystry TF, Brock R, Storm G and Prakash J: Anti-microRNA targeting using peptide-based nano-complexes to inhibit differentiation of human pancreatic stellate cells. *Nanomedicine (Lond)* 12: 1369-1384, 2017.
103. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G and Sood AK: RNA interference in the clinic: Challenges and future directions. *Nat Rev Cancer* 11: 59-67, 2011.
104. Ling H, Fabbri M and Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. *Nat Rev Drug Discov* 12: 847-865, 2013.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.